ClinicalTrials.gg
CompletedNCT01770392Updated Nov 27, 2014Results posted

Relative Bioavailability of a Single Dose of Nintedanib Given Alone and in Combination With Multiple Doses of Rifampicin

A Phase 1 interventional study of Nintedanib and Rifampicin in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in Germany. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-11-27.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
26
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

To investigate the effect of the P-gp inducer rifampicin on the pharmacokinetic parameters of nintedanib

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male subjects

Exclusion criteria

Exclusion criteria:

  1. Any relevant deviation from healthy conditions
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
26 participants (actual)

Study arms

  • Active comparator
    Test

    multiple doses of Rifampicin + single dose of Nintedanib

    Drug: Rifampicin · Drug: Nintedanib

  • Experimental
    Reference

    single dose of Nintedanib

    Drug: Nintedanib

Interventions

06

What researchers measure

Primary outcomes

  1. Area Under the Curve From 0 Extrapolated to Infinity (AUC0-∞)

    AUC0-∞ represents the Area under the concentration-time curve of nintedanib in plasma over the time interval from 0 extrapolated to infinity. For this endpoint, the "measured values" show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.

    Time frame: 1.5 hour (h) before the first drug administration and 0.5h, 1h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 36h, 48h and 72h after administration of nintedanib

  2. Maximum Measured Concentration (Cmax)

    Cmax represents the maximum concentration of nintedanib in plasma. For this endpoint, the "measured values" show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.

    Time frame: 1.5 hour (h) before the first drug administration and 0.5h, 1h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 36h, 48h and 72h after administration of nintedanib

Secondary outcomes

  1. Area Under the Curve From 0 to the Last Quantifiable Concentration (AUC0-tz)

    AUC0-tz represents the area under the plasma concentration-time curve of nintedanib from 0 to the last quantifiable analyte plasma concentration. For this endpoint, the "measured values" show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.

    Time frame: 1.5 hour (h) before the first drug administration and 0.5h, 1h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 36h, 48h and 72h after administration of nintedanib

07

Results

Posted Nov 27, 2014

Participant flow

Nintedanib
Participant flow — Nintedanib
MilestoneOverall Study
Started26
Completed26
Not completed0
Washout Period of at Least 14 Days
Participant flow — Washout Period of at Least 14 Days
MilestoneOverall Study
Started26
Completed25
Not completed1
Withdrew: Adverse event1
Nintedanib+ Rifampicin
Participant flow — Nintedanib+ Rifampicin
MilestoneOverall Study
Started25
Completed25
Not completed0

Outcome measures

PrimaryArea Under the Curve From 0 Extrapolated to Infinity (AUC0-∞)

AUC0-∞ represents the Area under the concentration-time curve of nintedanib in plasma over the time interval from 0 extrapolated to infinity. For this endpoint, the "measured values" show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.

Time frame:
1.5 hour (h) before the first drug administration and 0.5h, 1h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 36h, 48h and 72h after administration of nintedanib
Reported as:
Geometric mean · ng*h/mL
Area Under the Curve From 0 Extrapolated to Infinity (AUC0-∞)
ng*h/mLNintedanibNintedanib + Rifampicin
Area Under the Curve From 0 Extrapolated to Infinity (AUC0-∞)183 ± 36.189.4 ± 36.8
Statistical analysis
  • Nintedanib vs Nintedanib + Rifampicin · ANOVA · p = 1.0000 (p-value for ratio outside interval 0.8 - 1.25) · Geometric mean ratio in percentage: 50.12 · 90% CI 47.155 to 53.275The standard deviation is actually the geometric coefficient of variation (in %). The ratio has been calculated as (nintedanib+ rifampicin) divided by nintedanib (in %)
PrimaryMaximum Measured Concentration (Cmax)

Cmax represents the maximum concentration of nintedanib in plasma. For this endpoint, the "measured values" show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.

Time frame:
1.5 hour (h) before the first drug administration and 0.5h, 1h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 36h, 48h and 72h after administration of nintedanib
Reported as:
Geometric mean · ng/mL
Maximum Measured Concentration (Cmax)
ng/mLNintedanibNintedanib + Rifampicin
Maximum Measured Concentration (Cmax)22.1 ± 51.812.8 ± 43.4
Statistical analysis
  • Nintedanib vs Nintedanib + Rifampicin · ANOVA · p = 1.0000 (p-value for ratio outside interval 0.8 - 1.25) · Geometric mean ratio in percentage: 59.76 · 90% CI 53.829 to 66.348The standard deviation is actually the geometric coefficient of variation (in %). The ratio has been calculated as (nintedanib+ rifampicin) divided by nintedanib (in %).
SecondaryArea Under the Curve From 0 to the Last Quantifiable Concentration (AUC0-tz)

AUC0-tz represents the area under the plasma concentration-time curve of nintedanib from 0 to the last quantifiable analyte plasma concentration. For this endpoint, the "measured values" show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.

Time frame:
1.5 hour (h) before the first drug administration and 0.5h, 1h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 36h, 48h and 72h after administration of nintedanib
Reported as:
Geometric mean · ng*h/mL
Area Under the Curve From 0 to the Last Quantifiable Concentration (AUC0-tz)
ng*h/mLNintedanibNintedanib + Rifampicin
Area Under the Curve From 0 to the Last Quantifiable Concentration (AUC0-tz)173 ± 36.984.1 ± 38.1
Statistical analysis
  • Nintedanib vs Nintedanib + Rifampicin · ANOVA · p = 1.0000 (p-value for ratio outside interval 0.8 - 1.25) · Geometric mean ratio in percentage: 49.98 · 90% CI 46.886 to 53.286The standard deviation is actually the geometric coefficient of variation (in %). The ratio has been calculated as (nintedanib+ rifampicin) divided by nintedanib (in %).

Adverse events

Collected over From the first trial drug administration until up to 14 days after last trial drug administration, up to 28 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Nintedanib—0/26 (0%)5/26 (19.2%)
Washout Period—0/26 (0%)2/26 (7.7%)
Rifampicin—0/25 (0%)25/25 (100%)
Nintedanib + Rifampicin—0/25 (0%)4/25 (16%)
Most frequent other events
Most frequent other events
EventNintedanibWashout PeriodRifampicinNintedanib + Rifampicin
ChromaturiaRenal and urinary disorders0/260/2625/250/25
HeadacheNervous system disorders1/262/265/252/25
DiarrhoeaGastrointestinal disorders5/260/261/253/25
Faeces discolouredGastrointestinal disorders0/260/263/250/25
DizzinessNervous system disorders0/260/262/250/25
FlatulenceGastrointestinal disorders0/260/262/250/25
FatigueGeneral disorders0/260/262/250/25

Baseline characteristics

The treated set (TS) consists of all subjects who took at least one dose of study medication.

Age, Continuous
Age, Continuous(years)Overall Study
Mean37.3 ± 8.7
Sex: Female, Male
Sex: Female, Male(Participants)Overall Study
Female0
Male26
08

Study locations

1 site
  • 1199.162.1 Boehringer Ingelheim Investigational Site
    Biberach, Germany
09

References and documents

Publications

  • Luedtke D, Marzin K, Jungnik A, von Wangenheim U, Dallinger C. Effects of Ketoconazole and Rifampicin on the Pharmacokinetics of Nintedanib in Healthy Subjects. Eur J Drug Metab Pharmacokinet. 2018 Oct;43(5):533-541. doi: 10.1007/s13318-018-0467-9. PubMed 29500603 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2013, a primary completion of Mar 2013 and a completion of Mar 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2014, 1 year 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 15, 2013
First posted
Jan 17, 2013
Start
Jan 2013
Primary completionActual
Mar 2013
CompletionActual
Mar 2013
Results first posted
Nov 27, 2014
Last update
Nov 27, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 27, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01770392
Responsible party
Sponsor
First posted
Jan 17, 2013
Start date
Jan 2013
Primary completion
Mar 2013
Completion
Mar 2013
Results posted
Nov 27, 2014
Last update
Nov 27, 2014

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nintedanib

Start the discussion